Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study - Wikidata - awgldk - TriplyDB

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

http://www.wikidata.org/entity/Q35570253

about

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Tumor Metabolism, the Ketogenic Diet and β-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data Diffusion MRI in early cancer therapeutic response assessment.Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.Antiangiogenic therapies in glioblastoma multiforme.Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.High-field MRS in clinical drug development.Current evidence of temozolomide and bevacizumab in treatment of gliomas.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells.Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy.Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.Improved visibility of brain tumors in synthetic MP-RAGE anatomies with pure T1 weighting.Intracellular pH measured by 31 P-MR-spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy.Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.Intratumoral Concentrations and Effects of Orally Administered Micellar Curcuminoids in Glioblastoma Patients.(31) P MR spectroscopic imaging of the human prostate at 7 T: T1 relaxation times, Nuclear Overhauser Effect, and spectral characterization.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.[Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].

P2860

Q27025007-EF9C3CB7-803E-4D29-B68B-8B2F870EC468 Q28068654-8D10C678-3CFA-466C-A6E7-FA124C147FBA Q28069398-85583D6A-E595-4983-B392-8A69F72F4CEE Q28544667-6A85DBF6-9BB5-45C0-8BA8-98ACF83AE2BB Q30564565-82B53E57-9DEC-4B50-88B8-14CD708E6C23 Q31037179-139717E9-4B83-4A28-A8B9-1CC70846BD6C Q31115540-B213EF29-D874-4F92-86D6-8A8728C7EA1B Q33688593-3666F177-67BE-452A-9DF9-665443FB1E64 Q33778107-5211055F-A238-4534-8193-FD982EF97B25 Q33844943-51860C83-25E9-4CA7-B5CC-0D6AC97B0B97 Q34631627-FDE7A874-E86E-4154-B1EE-EEBDEDC055EF Q36235508-176AF5E4-EBB7-46B0-9AE5-2C83D091CE05 Q36641544-83B21D7D-54DB-4B33-9594-511F7B33194A Q36943903-C7EF0CF5-7A18-4046-9ECB-7F4986C08680 Q37153834-DFF9F642-8C2D-4FBB-A4D4-A8DA773B34CE Q37187727-BD11A531-AD7D-4B84-9AA0-CE9EB838BDF8 Q37348479-5C8EFD43-08A9-405A-9CA2-ABD32918EE1E Q38010802-90BF0213-BB89-4089-9E2A-F6D38DCB263A Q38066416-0B7DDFAE-1586-4A57-AEA5-AC0D47E832F1 Q38105614-DD846D45-1A38-47EC-ACCF-EC421069F5C6 Q38230650-F492EA55-CC17-4858-B27D-D3FDCCE42F09 Q38635290-B0CB7B23-3651-4A24-A714-5F628D701915 Q38957729-2DD00A31-F89B-49F5-87B1-B9BCDDB5545B Q41809732-C585B3D5-B677-48E4-87CC-682E44D44850 Q44391299-0BBEFD70-C114-409B-B3CC-3529158C51D5 Q44844537-767DE22D-9B60-41A7-A982-4869B081AD56 Q47114557-5CC655DE-11B9-4CA6-99DB-6D859FA880F7 Q48184512-121E24DA-7D63-4FF9-A39D-A2E24CEC14D9 Q48321992-0AB0FF9D-270D-4992-9967-333F79B50B0C Q48344360-9E161178-2B57-4F18-85AF-51BB4B3CC289 Q48658011-B8F55772-9F81-4DF4-92F2-D4844DA3C02E Q51099040-34933CDA-0379-4A0F-9BC3-419AFB210C37 Q52149377-65431BAE-1384-4EA1-8DFE-C5172E59273D Q55460812-80149F17-3891-46E4-9F3C-918BCBBBEE7C

P2860

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

http://www.wikidata.org/entity/Q35570253

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@ast

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@en

type

label

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@ast

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@en

prefLabel

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@ast

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@en

P1433

Q35570253-E2407E09-B349-43FD-99AE-08393D4CBB3E

P1476

Q35570253-B34EC382-90CE-4EAE-81FA-A594B392A518

P2093

Q35570253-511423A7-AD92-46E1-82AF-67118DBD0994

Q35570253-8F023293-D243-45D7-AA7F-B92CE580EEE7

Q35570253-A2DB6359-A05E-459F-893C-5B7BAD3BA59E

Q35570253-C9E4F40F-3A17-4D6E-A703-FFE10C98F980

Q35570253-D1C59D73-D387-480A-A5AD-EBEE260C6085

Q35570253-F4562ECB-BD45-4E4D-97D3-01B990E936AC

P2860

Q35570253-01027CAC-7EE4-4684-BF2B-BA4F8CC00AC2

Q35570253-013AC3C6-DCEA-4819-9F63-A35830FF9C5C

Q35570253-02DE6E80-9D09-46AC-9436-35AA92E6E9C6

Q35570253-03AEC94B-5355-4E3D-8581-D4E42A381212

Q35570253-0A33FA65-F69D-4A14-9490-1AAE9890B3A4

Q35570253-0B3C2E6D-DB6F-43F7-9CAB-BDC9AC83AFF3

Q35570253-0D09DC65-6630-488A-B6A8-46E0E2266393

Q35570253-12411179-4A9F-4737-8530-D1F403470726

Q35570253-140A2F00-6FC2-4E51-BE2F-780BA5F0AE69

Q35570253-166F0B3F-8791-4E03-A7C9-5B177649F0F0

P304

Q35570253-5B1960DA-F701-4A45-B010-26D9D19A23FA

P31

Q35570253-2E4D7695-D474-43CA-AC6C-7DE1FC533C8C

P356

Q35570253-2D00E88A-CB76-4EB0-9054-D172470D5137

P433

Q35570253-D2E887BA-50C3-451A-BEA1-25DBF3AB65A6

P478

Q35570253-33F58CAE-87FC-4136-8553-EBBC755F1D48

P50

Q35570253-189E268A-6D17-4B4B-8A5A-17F840492217

Q35570253-67674DA6-BC3C-45E1-A422-2A06A69537D5

P577

Q35570253-419D4E6A-5813-439F-A37E-ADE7ECB56BCC

P5875

Q35570253-7F1364B3-E945-4CF0-A54A-0B4DB5C035D8

P698

Q35570253-BFDB2154-720D-4CB9-889C-4705C70C53A0

P921

Q35570253-879A7703-DEB2-47E1-AD2B-7A6F4CC44406

P932

Q35570253-AEBEED37-5BF2-414A-AF4C-112B138C6756

P356

P1433

P1476

Bevacizumab impairs oxidative ...... gnetic resonance imaging study

@en

P2093

Joachim P Steinbach

http://www.w3.org/2001/XMLSchema#string

Johannes Rieger

http://www.w3.org/2001/XMLSchema#string

Jörg Magerkurth

http://www.w3.org/2001/XMLSchema#string

Oliver Bähr

http://www.w3.org/2001/XMLSchema#string

Sandra Anti

http://www.w3.org/2001/XMLSchema#string

Ulrich Pilatus

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor Detection by Nuclear Magnetic Resonance

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

Rapid three-dimensional MR imaging using the FLASH technique

Advances in functional and structural MR image analysis and implementation as FSL

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Improved optimization for the robust and accurate linear registration and motion correction of brain images

Fast robust automated brain extraction

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

P304

1349-1363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOR132

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51617809

http://www.w3.org/2001/XMLSchema#string

P698

21890539

http://www.w3.org/2001/XMLSchema#string

P921

P932

3223092

http://www.w3.org/2001/XMLSchema#string